

---

Developing a personalized approach to beta cell replacement for patients with a genetic form of diabetes

**Grant Award Details**

---

Developing a personalized approach to beta cell replacement for patients with a genetic form of diabetes

**Grant Type:** Inception - Discovery Stage Research Projects

**Grant Number:** DISC1-08868

**Project Objective:** To determine the functional requirement for NEUROGENIN3 in the differentiation, maintenance, function, and survival of human pancreatic endocrine cells.

**Investigator:**

<b>Name:</b>	Senta Georgia
<b>Institution:</b>	Children's Hospital of Los Angeles
<b>Type:</b>	PI

---

**Disease Focus:** Diabetes

**Human Stem Cell Use:** iPS Cell

**Cell Line Generation:** iPS Cell

**Award Value:** \$180,000

**Status:** Active

**Grant Application Details**

---

**Application Title:** Developing a personalized approach to beta cell replacement for patients with a genetic form of diabetes

**Public Abstract:****Research Objective**

To correct a gene mutation in a patient's stem cells and produce functional replacement cells for the patient to cure their diabetes.

**Impact**

WE expect that this project can serve as a model for developing new treatments for patients with certain forms of genetic diabetes.

**Major Proposed Activities**

- To understand how the patient's gene mutation affects the differentiation, function, and survival of stem cell derived insulin cells
- To correct the patient's mutation in stem cells, then generate new insulin cells and test if they are fully functional.

**Statement of Benefit to California:**

California is already a leader in advancing stem cell technology. If we are successful, we believe that California can become the center for patients with certain forms of diabetes to come to for treatment.

---

**Source URL:** <https://www.cirm.ca.gov/our-progress/awards/developing-personalized-approach-beta-cell-replacement-patients-genetic-form>